B.R.R. Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-06-2024
- Paid Up Capital ₹ 1.00 M
as on 30-06-2024
- Company Age 21 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -28.50%
(FY 2022)
- Profit -29.57%
(FY 2022)
- Ebitda -22.34%
(FY 2022)
- Net Worth -21.05%
(FY 2022)
- Total Assets -19.71%
(FY 2022)
About B.R.R. Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ramalinga Bhimireddy and Venkata Bhimireddy serve as directors at the Company.
- CIN/LLPIN
U24239TG2003PTC041050
- Company No.
041050
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 May 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at B.R.R. Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramalinga Bhimireddy  | Managing Director | 26-May-2003 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Bhimireddy | Director | 01-Jun-2005 | Current |
Financial Performance and Corporate Structure Insights of B.R.R. Pharmaceuticals.
B.R.R. Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 28.5% decrease. The company also saw a substantial fall in profitability, with a 29.57% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of B.R.R. Pharmaceuticals?
In 2019, B.R.R. Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alkri Plastics Private Limited
Active 11 years 8 monthsRamalinga Bhimireddy and Venkata Bhimireddy are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at B.R.R. Pharmaceuticals?
Unlock and access historical data on people associated with B.R.R. Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of B.R.R. Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped B.R.R. Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
